Alan Melcher shares his thoughts on lung cancer vaccine trials – The Institute of Cancer Research
The Institute of Cancer Research (ICR) shared on LinkedIn:
“It’s great to see a new type of immunotherapy being trialled, and particularly good to see that these cancer vaccines are being pioneered and championed within the NHS.
Cancer vaccines activate the immune system to respond against specific tumour antigens. We vaccinate against antigens in a virus too, but cancer’s antigens are much harder to target.
‘This vaccine uses a cheaper and easier approach – off-the-shelf rather than one that has to be personalised for each patient. If successful, this is a more practical way to give the vaccine to many more patients.’
Professor Alan Melcher, Translational Immunotherapy at the ICR shares his thoughts on lung cancer vaccine trials.
Read the article in full here.”